Paige Review - FDA Promotion Rules checks a US promotional piece against FDA’s prescription drug advertising regulation, 21 CFR 202.1, and FDA’s guidance on promotion. It checks the piece’s claims against the product’s Prescribing Information, once a person on your team has verified it in Papercurve.
This article lists every rule Paige checks, grouped the way the Coverage tab shows them. Each finding Paige raises cites the rule’s regulation, and the Coverage tab shows, for each review, which rules Paige checked, which didn’t apply to the piece, and which need a person. For how a review works, see Paige Review - FDA Promotion Rules; for common questions, including how it relates to OPDP, see Questions and Answers.
Paige Review is an assistant. It helps your team find problems early. It isn’t an FDA or OPDP opinion, and it doesn’t approve or release content: your reviewers still decide.
What Paige reviews
- Products: prescription drugs and biologics.
- Audiences: health care professionals and consumers.
- Media: print and electronic pieces: PDFs, and anything Papercurve turns into a PDF, such as Word, PowerPoint and image files.
- Languages: English, Spanish, and bilingual English and Spanish pieces. Spanish pieces are checked against the English Prescribing Information.
The rules
Risk presentation
| Rule |
Citation |
| Risk information is in the piece itself, not only as a link or reference to the Prescribing Information |
21 CFR 202.1(e)(5)(ii) |
| Risk is as prominent as benefit: type size, contrast and placement |
21 CFR 202.1(e)(7)(viii) |
| Risk is not minimized or played down |
21 CFR 202.1(e)(6)(iv) |
Boxed warning and key safety
| Rule |
Citation |
| The boxed warning is presented, when the product has one |
21 CFR 202.1(e)(5)(iii) |
| Contraindications and serious warnings are not left out |
21 CFR 202.1(e)(3)(iii) |
| Limitations of use and restrictions are stated |
21 CFR 202.1(e)(5)(iii) |
Claims beyond the label
| Rule |
Citation |
| The indication is stated in full and not broadened |
21 CFR 202.1(e)(6)(i) |
| Claims are consistent with the Prescribing Information |
21 CFR 202.1(e)(6)(i) |
| Dosing and administration match the Prescribing Information |
21 CFR 202.1(e)(6)(xvii) |
Efficacy claims and evidence
| Rule |
Citation |
| Efficacy is not overstated |
21 CFR 202.1(e)(6)(i) |
| The evidence can carry the claim: subgroup, post hoc, exploratory and single-arm results |
21 CFR 202.1(e)(7)(i) |
| The cited reference supports the claim |
21 CFR 202.1(e)(6)(x) |
| Comparisons have head-to-head support |
21 CFR 202.1(e)(6)(ii) |
| Quality-of-life and patient-reported claims have valid support |
21 CFR 202.1(e)(6)(i) |
| Material facts that qualify a claim are given, as prominently as the claim |
21 CFR 202.1(e)(5)(iii) |
Numbers and data
| Rule |
Citation |
| Relative results come with absolute ones |
21 CFR 202.1(e)(5)(iii) |
| Charts and graphics don’t distort |
21 CFR 202.1(e)(7)(iv) |
| Statistics are used properly |
21 CFR 202.1(e)(7)(ii) |
Product name
| Rule |
Citation |
| The established name accompanies the brand name, at least half its size |
21 CFR 202.1(b); 21 CFR 201.10(g) |
Scope and submission
| Rule |
Citation |
| The piece is one this rulebook covers (product, audience, medium, language) |
FD&C Act 502(n); 21 CFR 202.1(l) |
| Reminder pieces are recognized, and the rules that don’t apply to them are skipped |
21 CFR 202.1(e)(2)(i); 21 CFR 201.100(f) |
| The report’s checklist includes submission on Form FDA 2253 at first dissemination, and pre-submission for products under accelerated approval |
21 CFR 314.81(b)(3)(i) |
What Paige checks a piece against
- The piece itself: its words, its layout and type sizes, and its pictures and charts.
- The Prescribing Information: the indication, limitations of use, boxed warning, contraindications, warnings and precautions, dosing, and the clinical studies section, from the product card a person on your team verified.
- The studies the piece cites: when they are in Papercurve as reference documents.
FDA guidance behind the rules
- Presenting Risk Information in Prescription Drug and Medical Device Promotion (draft, 2009)
- Internet/Social Media Platforms with Character Space Limitations: Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices (draft, 2014)
- Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling (final, 2017)
- Medical Product Communications That Are Consistent With the FDA-Required Labeling: Questions and Answers (final, 2018)
- Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer (DTC) Promotional Labeling and Advertisements (final, 2023)
- Accelerated Approval: Expedited Program for Serious Conditions (draft, 2024)
- Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers (final, 2025)
Not covered yet
- TV, radio, video and audio, including the major statement for broadcast ads
- The brief summary format for consumer print ads
- Promotion of investigational products and uses
- Vaccines and blood products, medical devices, and over-the-counter products
A piece outside what Paige reviews gets no review, and the panel says why. For anything not covered, your team’s review is the check.